TY - JOUR
T1 - Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)
AU - Cosmai, Laura
AU - Gallieni, Maurizio
AU - Liguigli, Wanda
AU - Porta, Camillo
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Since angiogenesis plays a key role in tumor growth, progression and metastasization, anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) agents have been developed over the years as anticancer agents, and have changed, for the better, the natural history of a number of cancer types. In the present review, the renal safety profile of presently available agents targeting either VEGF or VEGFRs will be discussed, together with the peculiarities related to their clinical use in patients with impaired renal function, or even in dialysis. Indeed, renal toxicity (especially, but not exclusively, hypertension and proteinuria) are quite commonly observed with these agents, and may be increased by the concomitant use of cytoxic chemotherapeutics. Despite all the above, kidney impairment or dialysis must not be regarded di per se as reasons not to administer or to stop an active anticancer treatment, especially considering the possibility of a significant survival improvement in many cancer patients treated with these agents.
AB - Since angiogenesis plays a key role in tumor growth, progression and metastasization, anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) agents have been developed over the years as anticancer agents, and have changed, for the better, the natural history of a number of cancer types. In the present review, the renal safety profile of presently available agents targeting either VEGF or VEGFRs will be discussed, together with the peculiarities related to their clinical use in patients with impaired renal function, or even in dialysis. Indeed, renal toxicity (especially, but not exclusively, hypertension and proteinuria) are quite commonly observed with these agents, and may be increased by the concomitant use of cytoxic chemotherapeutics. Despite all the above, kidney impairment or dialysis must not be regarded di per se as reasons not to administer or to stop an active anticancer treatment, especially considering the possibility of a significant survival improvement in many cancer patients treated with these agents.
KW - Antiangiogenic agents
KW - Hypertension
KW - Proteinuria
KW - Renal toxicity
KW - VEGF
KW - VEGFR
UR - http://www.scopus.com/inward/record.url?scp=85015767621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015767621&partnerID=8YFLogxK
U2 - 10.1007/s40620-016-0311-8
DO - 10.1007/s40620-016-0311-8
M3 - Review article
C2 - 27154025
AN - SCOPUS:85015767621
VL - 30
SP - 171
EP - 180
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 2
ER -